Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
Robert Landewé,
Désirée van der Heijde,
Atul Deodhar,
Martin Rudwaleit,
Lianne S Gensler,
Walter P Maksymowych,
Bengt Hoepken,
Lars Bauer,
Thomas Kumke,
Mindy Kim,
Simone Emanuele Auteri
Affiliations
Robert Landewé
Rheumatology Department, Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, The Netherlands
Désirée van der Heijde
Rheumatology Department, Leiden University Medical Center, Leiden, Zuid-Holland, The Netherlands
Atul Deodhar
3 Oregon Health & Science University, Portland, Oregon, USA
Martin Rudwaleit
Department of Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Lianne S Gensler
32 Division of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA
Walter P Maksymowych
1 Medicine, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada
